TransMedics Reports Second Quarter 2026 Financial Results
TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised revenue guidance range and the quarterly revenue growth drivers (OCS utilization via NOP plus logistics services), offset by YoY gross margin softness and higher operating expenses tied to platform and clinical investments.
Market read
This is a direct earnings-and-guidance update with a specific guidance raise, which typically drives near-term positioning and revisions to forward estimates.
What to watch
The guidance explicitly excludes PAD Aviation revenue and assumes no incremental revenue from ENHANCE Part B and DENOVO trials, so upside may be constrained until those assumptions change.
Background
TransMedics reports Q2 2026 results and updates 2026 revenue outlook, alongside a strategic investment in PAD Aviation to build an organ transplantation air logistics network.
Ticker impact
TransMedics raised full-year 2026 revenue guidance low end to $737M-$757M and reported Q2 revenue of $189.9M, up 21% YoY.
Likely positive bias for the next session and into guidance-follow-through, with volatility around margin and expense commentary.
The article discloses a fresh guidance change and quarterly results with specific revenue and income figures, while also noting gross margin down YoY and higher operating expenses from planned investments.
Market effects
Reinforces demand momentum for organ preservation and transplant logistics platforms, potentially supporting sentiment across transplant-adjacent medtech.
Limited direct regional read-through; PAD Aviation investment is Europe-focused but not quantified in revenue terms.
Europe air-logistics expansion narrative may broaden perceived addressable market for transplant logistics services.
Counterpoint
Gross margin fell YoY (60% vs 61%) and operating expenses rose sharply, so the guidance raise could reflect revenue mix and utilization rather than durable profitability improvement.
Key entities
- public_companyTransMedics Group, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and raising 2026 revenue guidance.
- private_companyPAD Aviation service GmbH
Germany-based private aviation operator in which TransMedics completed a strategic investment on July 1, 2026.